Pathogenesis of peritoneal sclerosis

International Journal of Artificial Organs

Volumn 28, Issue 2, 2005, Pages 90-96

  Pollock, Carol ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Bioincompatible dialysate; Encapsulating peritoneal sclerosis; Peritoneal sclerosis

Indexed keywords

BIOCOMPATIBILITY; CELL CULTURE; DECISION MAKING;

BIOINCOMPATIBLE DIALYZATE; CONDITION; DIALYSATES; ENCAPSULATING PERITONEAL SCLEROSE; PERITONEAL DIALYSIS; PERITONEAL SCLEROSE; PERITONEAL TRANSPORT; SIMPLE++; TRANSPORT LOSS; TRANSPORT RATE;

DIALYSIS;

ADVANCED GLYCATION END PRODUCT; ANTIBIOTIC AGENT; CONNECTIVE TISSUE GROWTH FACTOR; CYTOKINE; GLUCOSE; ICODEXTRIN; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; OCTREOTIDE; PERITONEAL DIALYSIS FLUID; PLATELET DERIVED GROWTH FACTOR AB; SCATTER FACTOR; TRANSFORMING GROWTH FACTOR BETA1;

BIOCOMPATIBILITY; CLINICAL FEATURE; CORRELATION FUNCTION; DATA ANALYSIS; DEATH; DIALYSATE; DIALYSIS MEMBRANE; DISEASE ASSOCIATION; EXPOSURE; FIBROBLAST; FIBROSIS; GLYCATION; HISTOPATHOLOGY; HUMAN; IMMUNE RESPONSE; INFLAMMATORY CELL; INTESTINE OBSTRUCTION; LEUKOCYTE FUNCTION; MALNUTRITION; MEDICAL DECISION MAKING; MESOTHELIUM CELL; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; OXIDATIVE STRESS; PATHOGENESIS; PERITONEAL BIOPSY; PERITONEAL DIALYSIS; PERITONEUM; PERITONITIS; REGISTER; REVIEW; SCLEROSIS; ULTRAFILTRATION;

EID: 16844378549     PISSN: 03913988     EISSN: None     Source Type: Journal    
DOI: 10.1177/039139880502800203     Document Type: Review

References (40)

1. Williams JD, Craig KJ, Topley N, Von Ruhland C, Fallon M, Newman GR, MacKenzie RK, Williams GT. Peritoneal Biopsy Study Group. Morphologic changes in the peritoneal membrane of patients with renal disease. J Am Soc Nephrol 2002; 13: 470-9.
2. Mateijsen MA, vanderWal AC, Hendriks PM, Zweers MM, Mulder J, Struijk DG, Krediet RT. Vascular and interstitial changes in the peritoneum of CAPD patients with peritoneal sclerosis. Perit Dial Int 1999; 19: 517-25.
3. Plum J, Hermann S, Fussholler A, Schoenicke G, Donner A, Rohrborn A, Grabensee B. Peritoneal sclerosis in peritoneal dialysis patients related to dialysis settings and peritoneal transport properties. Kidney Int 2001; 78 (suppl): S42-7.
4. Williams JD, Craig KJ, von Ruhland C, Topley N, Williams GT. The natural course of peritoneal membrane biology during peritoneal dialysis. Kidney Int 2003; 64: (suppl 88): S43-9.
5. Coles GA, Williams JD, Topley N. Peritoneal inflammation and long-term changes in peritoneal structure and function. In: Gokal R, Khanna R, Krediet R, Nolph KD, eds. Textbook of peritoneal dialysis. Dordrecht: Kluwer Academic Publishers 2000; pp. 565-83.
6. Yanez-Mo M, Lara-Pei E, Selgas R, Ramirez-Huesca M, Dominguez-jimenez C, Jimenez-Heffernan JA, Aguilera A, Sanchez-Tomero JA, Bajo MA, Alvarez V, Castro MA, del Peso G, Cirujeda A, Gamallo C, Sanchez-Madrid F, Lopez-Cabrera M. Peritoneal dialysis and epithelial-to-mesenchymal transition of mesothelial cells. New Engl J Med 2003; 348: 403-13.
7. Okada H, Inoue T, Kanno Y, Kobayashi T, Watanabe Y, Ban S, Neilson EG, Suzuki H. Selective depletion of fibroblasts preserves morphology and the functional integrity of peritoneum in transgenic mice with peritoneal fibrosing syndrome. Kidney Int 2003; 64: 1722-32.
8. Ha H, Yu MR, Lee HB. High glucose-induced PKC activation mediates TGFB, and fibronectin synthesis by peritoneal mesothelial cells. Kidney Int 2001; 59: 463-70.
9. Masunaga Y, Asakura S, Muto S, Ando Y, Homma S, Kusano E, Matsuda M, Asano Y. Multimeric vitronectin in ascites is involved in fibroblast spreading of EPS in patients on CAPD therapy. Clin Exp Nephrol 2003; 7: 150-6.
10. Pawlaczyk K, Kuzlan-Pawlaczyk, Anderstam B, Heimburger O, Bergstrom J, Waniewski J, Breborowicz A, Lindholm B. Effects of intraperitoneal heparin on peritoneal transport in a chronic model of peritoneal dialysis. Nephrol Dial Transplant 2001; 16: 669-71.
11. Beavis MJ, Williams JD, Hoppe J, Topley N. Human peritoneal fibroblast proliferation in 3-dimensional culture: Modulation by cytokines, growth factors and peritoneal dialysis effluent. Kidney Int 1997; 51: 205-15.
12. Naiki Y, Maeda Y, Matsuo K, Yonekawa S, Sakaguchi M, Iwamoto I, Hasegawa H, Kanamaru A. Involvement of TGF-beta signal for peritoneal sclerosing in continuous ambulatory peritoneal dialysis. J Nephrol 2003; 16: 95-102.
13. Gunal AI, Celiker H, Ustundag B, Akpolat N, Dogukan A, Akcicek F. The effect of oxidative stress inhibition with trimetazidine on the peritoneal alterations induced by hypertonic peritoneal dialysis solutions. J Nephrol 2003; 16: 225-30.
14. Yang AH, Chen JY, Lin JY. Myofibroblastic conversion of mesothelial cells. Kidney Int 2003; 63: 1530-9.
15. Zarrinkalam KH, Stanley JM, Gray J, Oliver N, Faull RJ. Connective tissue growth factor and its regulation in the peritoneal cavity of peritoneal dialysis patients. Kidney Int 2003; 64: 331-8.
16. Margetts PJ, Kolb M, Yu L, Hoff CM, Holmes CJ, Anthony DC, Gauldie J. Inflammatory cytokines, angiogenesis and fibrosis in the rat peritoneum. Am J Pathol 2002; 160: 2285-94.
17. Devuyst O, Topley N, Williams JD. Morphological and functional changes in the dialysed peritoneal cavity: Impact of more biocompatible solutions. Nephrol Dial Transplant 2002; 17 (suppl 3): S12-5.
18. Miyata T, Devuyst O, Kurokawa K, van Ypersele de Strihou C. Toward better dialysis biocompatibility: Advances in the biochemistry and pathophysiology of the peritoneal membranes. Kidney Int 2002; 61: 375-86.
19. Selgas R, del Peso G, Bajo MA, Molina S, Cirugeda A, Sanchez-Tomero JA, Castro MJ, Castro MA, Vara F. Vascular endothelial growth factor (VEGF) levels in peritoneal dialysis effluent. J Nephrol 2001; 14: 270-4.
20. Zweers MM, de Waart DR, Smit W, Struijk DG, Krediet RT. Growth factors VEGF and TGFB1 in peritoneal dialysis. J Lab Clin Med 1999; 134: 124-32.
21. Williams JD, Topley N, Craig KJ, Mackenzie RK, Pischetsrieder M, Lage C, Passlick-Deetjen J. Euro Balance Trial Group. Kidney Int 2004: 66: 408-18.
22. De Vriese AS, Flyvbjerg A, Mortier S, Tilton RG, Lamiere NH. Inhibition of the interaction of AGE-RAGE prevents hyperglycaemia-induced fibrosis of the peritoneal membrane. J Am Soc Nephrol 2003; 14: 2109-18.
23. Basile C, De Padova F, Montanaro A, Giordano R. The impact of relapsing sterile icodextrin-associated peritonitis on peritoneal dialysis outcomes. J Nephrol 2003; 16: 384-6.
24. Nakamoto H, Imai H, Ishida Y, Yamanouchi Y, Inoue T, Okada H, Suzuki H. New animal models for encapsulating peritoneal sclerosis - role of acidic solution. Perit Dial Int 2001; 21 (suppl 3): S349-93.
25. Imai H, Nakamoto N, Fukushima R, Ishida R, Ishida Y, Yamanouchi Y, Suzuki H. Role of adhesion molecules in the progression of peritoneal sclerosis. Adv Perit Dial 2003; 19: 180-5.
26. Wieczorowska K, Polubinska A, Schaub TP, Schilling H, Wisniewska J, Witowski J, Passlick-Deetjen J, Breborowicz A. Influence of neutral pH dialysis solutions on the peritoneal membrane: A long-term investigation in rats. Perit Dial Int 2001; 21 (suppl 3): S108-13.
27. Fischereder M, Schroppel B, Wiese P, Fink M, Banas B, Schmidbauer S, Schlondorff D. Regulation of glucose transporters in human peritoneal mesothelial cells. J Nephrol 2003; 16: 103-9.
28. Ha H, Cha MK, Choi HN, Lee HB. Effects of peritoneal dialysis solutions in the secretion of growth factors and extracellular matrix proteins by human peritoneal mesothelial cells. Perit Dial Int 2002; 22: 171-7.
29. Moriishi M, Kawanishi H, Kawai T, Takahashi S, Hirai T, Sishida M, Watanabe H, Takahashi N. Influence of pH-neutral peritoneal dialysis solution. Adv Perit Dial 2002; 18: 68-71.
30. Stigant CE, Bargman JM. Bicarboate/lactate-based peritoneal dialysis solution increases cancer antigen 125 and decreases hyaluronic acid levels. Kidney Int 2001; 59: 1529-38.
31. Jones S, Holmes CJ, Kreediet RT, Mackenzie R, Faict D, Traneus A, Williams JD, Coles GA, Topley N. What's new in peritoneal dialysis: Biocompatibility and continuous flow peritoneal dialysis. Curr Opin Nephrol Hypertens 2002; 11: 597-602.
32. Afthentopoulos IE, Passadakia P, Oreopoulos D. Sclerosing peritonitis in continuous ambulatory peritoneal dialysis patients. One centre's experience and review of the literature. Adv Ren Replace Ther 1998; 5: 157-67.
33. Campbell S, Clarke P, Hawley C, Wigan M, Kerlin P, Butler J, Wall D. Sclerosing peritonitis: Identification of diagnostic, clinical and radiological features. Am J Kidney Dis 1994; 24: 819-25.
34. Nakayama M, Yamamoto H, Ikeda M, Hasegawa T, Kato N, Takahashi N, Otsuka Y, Yokoyama K, Yamamoto R, Kawaguchi Y, Hosoya T. Risk factor and preventive measures for encapsulating peritoneal sclerosis - Jikei experience 2002. Adv Perit Dial 2002; 18: 144-8.
35. Bertoli SV, Buzi L, Ciurlino D, Maccarioi M, Martino S. Morpho-functional study of peritoneum in peritoneal dialysis patients. J Nephrol 2003; 16: 373-8.
36. Nakamoto H, Kawaguchi Y, Suzuki H. Encapsulating peritoneal sclerosis in patients undergoing continuous ambulatory peritoneal dialysis in Japan. Adv Perit Dial 2002; 18: 119-23.
37. Yamamoto H, Nakayama M, Yamamoto R, Otsuka Y, Takahashi H, Kato N, Hayakawa H, Hasegawa T, Ikeda M, Yokoyama K, Kawaguchi Y, Mukai H, Hosoya T. Fifteen cases of encapsulating peritoneal sclerosis related to peritoneal dialysis: A single centre experience in Japan. Adv Perit Dial 2002; 18: 135-8.
38. Yamamoto R, Nakayama M, Hasegawa T, Miwako N, Yamamoto H, Yokoyami K, Ikeda M, Kato N, Hayakawa H, Takahashi H, Otsuka Y, Kawaguchi Y, Hosoya T. High transport membrane is a risk factor for encapsulating peritoneal sclerosis developing after long-term continuous peritoneal dialysis treatment. Adv Perit Dial 2002 18: 131-4.
39. Lai KN, Lai KB, Lam CWK, Chan TM, Li FK, Leung JCK. Changes of cytokine profiles during peritonitis in patients on continuous ambulatory peritoneal dialysis. Am J Kidney Dis 2000: 35: 644-52.
40. Mortier S, De Vriese AS, Leyssens A, Vanacker NJ, Faict D, Cornelissen M, De Ridder L, Lamiere NH. Antibiotic administration in an animal model of chronic peritoneal dialysate exposure. Perit Dial Int 2003; 23: 331-8.